Highlights in clinical autonomic neurosciences: device-based therapy for resistant hypertension

Comment

Satish R Raj. Auton Neurosci. 2012.

. 2012 Jan 26;166(1-2):1-3.

doi: 10.1016/j.autneu.2011.11.003. Epub 2011 Dec 1.

No abstract available

Comment on

Novel baroreflex activation therapy in resistant hypertension: results of a European multi-center feasibility study.
Scheffers IJ, Kroon AA, Schmidli J, Jordan J, Tordoir JJ, Mohaupt MG, Luft FC, Haller H, Menne J, Engeli S, Ceral J, Eckert S, Erglis A, Narkiewicz K, Philipp T, de Leeuw PW. Scheffers IJ, et al. J Am Coll Cardiol. 2010 Oct 5;56(15):1254-8. doi: 10.1016/j.jacc.2010.03.089. J Am Coll Cardiol. 2010. PMID: 20883933 Clinical Trial.
Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial.
Symplicity HTN-2 Investigators; Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Böhm M. Symplicity HTN-2 Investigators, et al. Lancet. 2010 Dec 4;376(9756):1903-9. doi: 10.1016/S0140-6736(10)62039-9. Epub 2010 Nov 17. Lancet. 2010. PMID: 21093036 Clinical Trial.
Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months.
Symplicity HTN-1 Investigators. Symplicity HTN-1 Investigators. Hypertension. 2011 May;57(5):911-7. doi: 10.1161/HYPERTENSIONAHA.110.163014. Epub 2011 Mar 14. Hypertension. 2011. PMID: 21403086 Clinical Trial.